Need immediate assistance? Call 1-518-730-0559 (Us-Canada Toll Free) or Contact Us


Hypertrophic Cardiomyopathy Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2015 - 2023

Report Description

Hypertrophic cardiomyopathy (HCM) is a disease of the heart muscles (myocardium) in which thickening of myocardium causes functional impairment. It is a genetic condition caused by mutation in one or more genes and is hereditary in nature. According to the European Society of Cardiology, prevalence of HCM was between 0.05% and 0.2% of the population in 2013. A study published in BioMed Central in 2010 stated that there was no significant gender and age range differences in the prevalence of HCM. Prevalence of HCM is higher among African-Americans compared to other races. The global hypertrophic cardiomyopathy therapeutics market was valued at USD 1,216.3 million in 2014 and is projected to reach USD 1,378.4 million by 2023, expanding at a CAGR of 1.4% during the forecast period.

The global hypertrophic cardiomyopathy therapeutics market has been broadly categorized into drug class and geography. Beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, and anticoagulants together constitute the drugs class segment of the hypertrophic cardiomyopathy therapeutics market. Calcium channel blockers was the largest segment in 2014, although beta adrenergic blocking agents were the first choice for treatment of obstructive and non-obstructive HCM. Price of calcium channel blockers is higher than beta adrenergic blocking agents; hence, in terms of revenue, calcium channel blockers dominated the hypertrophic cardiomyopathy therapeutics market in 2014. A similar trend is expected to continue during the forecast period. Calcium channel blockers are anticipated to expand at a CAGR of 1.8% from 2015 to 2023.

Geographically, the hypertrophic cardiomyopathy therapeutics market has been segmented into four regions: North America, Europe, Asia Pacific, and Rest of the World (RoW). The market is primarily concentrated in the U.S., followed by Europe. The U.S. was the most attractive market for hypertrophic cardiomyopathy therapeutics in 2014, with more than 30% share of the global market. Europe accounted for the second-largest share of the global market in 2014. In 2014, the U.S. and Europe primarily dominated the hypertrophic cardiomyopathy therapeutics market due to modern healthcare infrastructure, increasing sedentary lifestyle among the youth, and rising obese population. Additionally, high awareness about HCM in developed countries boosts the market growth. North America is expected to continue its dominance during the forecast period. Asia Pacific was the fastest growing markets due to rising disease prevalence, developing healthcare infrastructure, and increasing awareness about cardiac complications in these regions. However, technological advancements in devices such as defibrillators and pacemakers are estimated to hamper market growth. This, in turn, would restrict the uptake of hypertrophic cardiomyopathy drugs. Thus, market leaders are recommended to focus on the development of new drugs or combination drugs that are specifically targeted toward hypertrophic cardiomyopathy in order to gain competitive advantage in the market.

AstraZeneca plc, Concordia Healthcare Corp., Sanofi S.A., Pfizer, Inc., Merck & Co., Inc., Teva Pharmaceuticals Limited, Mylan N.V., Gilead Sciences, Inc., and Novartis AG are some of the major companies operating in the global hypertrophic cardiomyopathy therapeutics market.

Custom Market Research Services

MRRSE offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Get A Free Custom Research Quote